CKD Bio Corp
KRX:063160
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
19 160
24 500
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| KR |
|
CKD Bio Corp
KRX:063160
|
116.6B KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
529.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
277.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.9B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
222B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
269.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.8B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
96.9B EUR |
Loading...
|
Market Distribution
| Min | -163 055.6% |
| 30th Percentile | -2.2% |
| Median | 2.7% |
| 70th Percentile | 6.8% |
| Max | 22 874.8% |
Other Profitability Ratios
CKD Bio Corp
Glance View
CKD Bio Corp. engages in the development and manufacture of active pharmaceutical ingredients. The company is headquartered in Seoul, Seoul. The company went IPO on 2001-12-11. The firm mainly provides antibiotic ingredients, consisting of demethylchlortetracyclines (DMCTs) and rifampicins. The company also provides immunosuppressive agents, including cyclosporin and tacrolimus; remedies for diabetes, such as acarbose, and potassium clavulanate used for beta-lactam inhibitors. The firm distributes its products within domestic market and to overseas markets, such as America, China, Europe, Africa, Southeast Asia, Latin America and the Middle East.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for CKD Bio Corp is 2.5%, which is above its 3-year median of -4.1%.
Over the last 3 years, CKD Bio Corp’s Operating Margin has increased from -5.8% to 2.5%. During this period, it reached a low of -15.7% on Sep 30, 2023 and a high of 6.4% on Dec 31, 2024.